Supriya Lifescience Limited
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
What Supriya files
- Investor Meet52
- Others44
- Updates18
- Board Meeting10
- Important10
- PPTs7
Supriya Lifescience's board approved the financial results for the quarter. Revenue from operations reached ₹189.75 Cr, with net profit at ₹24.04 Cr (EPS ₹2.99). An export shipment was detained by Customs, but revenue was recognized. Investors note operational resilience.
Supriya Lifescience's board has approved its financial results for the quarter ended June 30, 2025. Revenue from operations for the quarter stood at ₹145.07 Cr, down from ₹160.63 Cr in the same quarter last year. Net profit for the period was ₹34.79 Cr, a decline from ₹44.64 Cr year-on-year. EPS...
Supriya Lifescience clarifies it is a distinct entity from Supriya Pharmaceuticals, with no operational affiliation or control over its shareholder services. This addresses recent investor queries regarding share dematerialization for Supriya Pharmaceuticals. Supriya Lifescience confirms all its shares are in Demat form, with zero physical shareholding. Shareholders of Supriya Pharmaceuticals...
Supriya Lifescience has announced a board meeting on the financial results for the quarter and half-year. The company received a Show Cause Notice from the GST Department alleging double benefit refund claims amounting to Rs 60.38 Cr (tax and penalty combined). Supriya Lifescience disputes the demand, is contesting it in...
Supriya Lifescience has announced a board meeting to consider the financial results for the quarter and half-year. The board has proposed a final dividend of Re. 1.00 (50%) per share of Rs. 2 face value for FY 2024-25, subject to shareholder approval. Dividend distribution will be subject to tax deduction...